Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2003; 49(6): 56-63

Mechanisms of inhibiting thymic serum activity at tumor growth

F.V.Filchakov, T.N.Selezneva

    Institute of Oncology AMS of Ukraine, Kiev



Abstract

The experiments were conducted on a model of intraorganic growth of Geren carcinoma (GC) in spleen of non-linear mice. It has been shown that titer of thymic serum activity (TSA) decreased sharply in the blood at a stage of settling transplants down (7th day) , while the level of an inhibitor for thymic serum factor (FTS) increased in a statistically significant way. At progressive tumor growth, the level of TSA in the circulation raised a little on the 10th day but it was still reduced in comparison with that before inoculation of GC. Traces of the inhibitor for FTS were detected only in 18 and 25 days of tumor growth. We have found resemblance between these substances and those in low-molecular extracts of lymphocytes (LEL). The LEL from cells of the spleen and the thymus of intact rats contained TSA and FTS inhibitor, both of T-cell origin, in ratio 1:1. Production of TCA and the FTS inhibitor was peculiar to immature cortisone-sensitive T-lymphocytes. Anti-FTS serum in vitro completely neutralized TSA in both the blood and an extract of thymocytes but it effected neither the contents of TSA in the LEL of the spleen nor the level of FTS inhibitor in all the samples investigated. The data received testify to an important role of FTS inhibitor in the pathogenesis of tumor progression.

Full text: (PDF, in Ukrainian)

References

  1. Гриневич Ю.А., Никольский И.С., Титоренко Л.А., Селезнева Т.Н. Содержание тимического сывороточного фактора и чувствительность лимфоцитов перефирической крови к тимостимулину и теофиллину при предраковых заболеваниях и раке молочной железы // Иммунология. – 1982. –№5. – С. 48 – 51.
  2. Гриневич Ю.А., Бебешко В.Г., Никольский И.С. и др. Эндокринная функция тимуса и некоторые маркерные характеристики лимфоцитов периферической крови при лимфопролиферативных заболеваний у детей// Педиатрия. – 1985. – №8. – С.35 – 37.
  3. Гриневич Ю.А., Каменец Л.Я., Селезнева Т.Н. и др. Тимическая сывороточная активность у больных раком желудка и пищевода и ее изменения под влиянием комбинированного лечения с включением иммунотерапии // Клин. хирургия. – 1988. – №5. – С.19 – 22.
  4. Иммунобиология гормонов тимуса / Под ред. Ю.А.Гриневича, В.Ф.Чеботарева. – К.: Здоров’я, 1989. – 152 с.
  5. Методы исследований в иммунологии / Под ред. И. Лефковитса, Б. Перниса. – М.: Мир, 1981. – 485 с.
  6. Никольский И.С.,Селезнева Т.Н., Замотаева Г.А. и др. О продукции веществ с тимозинподобной активностью В-и Т-лимфоцитами // Журн. гигиены эпидемиологии, микробиологии и иммунологии. – 1990. – 34, № 3. – С. 341 – 347.
  7. Терновой К.С., Селезнева Т.Н., Ермекова В.М. Ингибирование тимической сывороточной активности доноров сыворотками больных системнойкрасной волчанкой, ревматоидным артритом и тимэктомированных мышей // Докл. АН УССР. Сер.Б. – 1988. – №10. – С.78 – 80.
  8. Терновой К.С., Ермекова В.М., Селезнева Т.Н.Возможности и перспективы многопараметрового иммунологического обследования в диагностике и прогнозе ревматоидного артрита // Ортопедия, травматология и протезирование. – 1989. – №3. – С.45 – 48.
  9. 9. Терновой К.С., Ермекова В.М., Селезнева Т.Н.Природа ингибиторов тимической сывороточной активности // Докл. АН УССР. Сер.Б. – 1990. – №3. – С.81 – 84.
  10. 10. Bach J.F., Dardenne M. Studies on thymus products II. Demonstration and characterization of circulating Thymic hormone // Immunology. – 1973. – 25. – P. 353 – 362.
  11. Bach J.F., Dardenne M., Pleau J.M., Bach M.A. Isolaion, biochemical characteristics, and biological activity of a circulating Thymic hormone in the mouse and in the human // Ann. N.Y. Acad. Sci. – 1975. – 249. – P. 186 – 210.
  12. Bach J.-F., Bach M.A., Blanot D., Bricas E., Charreire J. Dardenne M., Fournier C., Pleau J.-M. Thymic serum factor (FTS) // Bull. l’Institut Pasteur. – 1978. – 76. – P.325 – 398.
  13. Bach M.A., Beaurain G. Respective influence of extrinsic and intrinsic factors on the age-related decrease of Thymic secretion // J.Immunol. – 1979. – 122. – P. 2505 – 2507.
  14. Consolini R., Oti B., Cini P. et al. Circulating Thymic hormone activity in young cancer patients // Clin. and Exp.Immunol. – 1986. – 66. – P. 173 – 180.
  15. Consolini R., Legitimo A., Giorgianni A., Putti M.C. Thymic Dysfunction in Childhood T-Acute Lymphoblastic Leukemia – A Possible Linkage with a Primary Thymus Involvement // Haematologica. – 1992. – 77. – P. 243 – 247.
  16. Dardenne M., Pleau J.M., Savino W., Bach J.F. Monoclonal antibody against the serum thymic factor (FTS) // Immunology Letters. – 1982. – 4. – P. 79 – 83.
  17. Dardenne M., Savino W., Duval D. et al. Thymic hor-ono-containing cells.VII Adrenals and gonads control in vivo secretion of thymulin and its plasmatic inhibitor // J. Immunol. – 1986. – 136, №4. – Р. 1303 – 1308.
  18. Fabris N., Mocchegiani E., Amadio L. еt al. Thymic hormone eficiency in normal aging and Down’s syndrome there a primary failure of the thymus // Lancet. – 1984. – 1, № 8384. – P. 983 – 986.
  19. 19. Ohga K., Incefy G., Wang C.Y., Good R.A. Generation of monoclonal antibody against facteur thymique serique (FTS) // Clin. Exp. Immunol. – 1982. – 47. – P. 725 – 734.
  20. 20. Selezneva T.N., Ternovoi K.S., Yermecova V.M. Thymic serum activity inhibitors study // Int. J.Immunopharmac. – 1992. – 14, №4. – P. 667 – 669.
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.